|
|
Cancer Diagnostic Testing World Markets |
|
|
|
Cancer testing is one of the most important growth opportunities for the next three to five years in the diagnostics segment. The National Cancer Institute estimates that about ten million Americans have or have had some form of cancer. Overall costs of the disease are $126 billion annually. Pharmaceutical companies are developing more than 300 new medicines for cancer, some of which are in development for more than one type of the disease, for a total of more than 500 ongoing R&D projects. The goal of this Publications report is to review the market for tumor marker testing equipment and supplies using screening reagents and instruments for analysis of individual components in blood, serum or plasma. It defines the dollar volume of sales, both worldwide and in the U.S., and analyzes the factors that influence the size and the growth of the market segments. Also examined are the subsections of each market segment, including: the physician office labs, hospital labs and commercial laboratories. Additionally, the numbers of institutions using this type of testing and the factors that influence purchases are discussed. The report surveys almost all of the companies known to be marketing, manufacturing or developing instruments and reagents for the clinical point-of-care market in the U.S. Each company is discussed in depth with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company’s market position.
|
|
|
|
Table of Contents : |
1. Overview 8
1.1 Statement of Report 8
1.2 About This Report 8
1.3 Scope of the Report 9
1.4 Objectives 10
1.5 Methodology 10
1.6 Executive Summary 11
2. Introduction to Cancer Biology and the Diagnostic Industry 14
2.1 Cancer 14
2.1.1 The Disease 14
2.1.2 Metastasis 14
2.1.3 Demographics and Statistics of Cancer 14
2.2 The Drivers of the Biotech and Diagnostics Industry 19
2.2.1 Technological Innovation 20
2.2.2 Government Funding 21
2.3 Outlook for Tumor Markers 21
3. Tumor Markers Market Segment Analysis: Size, Growth and Share 23
3.1 Market Description 24
3.2 Clinical Diagnostic Serum Based Cancer Markers 31
3.3 PSA Testing Market Size 32
3.4 DNA Markers 33
3.5 Serum Proteins 33
3.6 Enzymes 34
3.7 Occult Blood 34
3.8 Histology and In Situ Hybridization (ISH) 35
3.9 Cervical Cytology 36
3.10 Immunohistochemistry 38
3.11 In Vivo Detection Cancer Products 39
3.12 Radionuclides and X-Ray Detection Products 39
3.13 Human Papillomavirus (HPV) Testing 39
3.14 Bladder Cancer Testing 43
3.15 Tumor Assays for Adjuvant Chemotherapy 46
4. Diagnostic Methods for Cancer Detection 59
4.1 Organ Specific Tumor Markers 59
4.1.1 Colon Cancer 59
4.1.2 Prostate Cancer 66
4.1.3 Pancreatic Cancer 83
4.1.4 Breast Cancer 85
4.1.5 Ovarian Cancer 94
4.1.6 Cervical Cancer 99
4.1.7 Lung Cancer 101
4.1.8 Testicular Cancer 106
4.1.9 Bladder Cancer 106
4.1.10 Hepatic Cancer 112
4.1.11 Stomach Cancer 114
4.1.12 Malignant Melanoma 115
4.1.13 Acute Myeloid Leukemia (AML) and Acute Lymphoblastoid Leukemia (ALL) 115
4.1.14 Lymphoma 116
4.2 Clinical Laboratory Methods for Measuring Tumor Markers 117
4.2.1 Abbott Diagnostics AxSYM 117
4.2.2 Roche Diagnostics Elecsys 117
4.2.3 Beckman Coulter Diagnostics Access 117
4.2.4 Bayer Diagnostics ADVIA Centaur 118
4.2.5 Dade Diagnostics Stratus 118
4.2.6 Diagnostic Products Corporation Immulite 118
4.2.7 Tosoh Medics A1A 119
4.2.8 CIS bio International Kryptor 120
4.2.9 Ortho-Clinical Diagnostics Vitros ECiQ 120
4.2.10 Fujirebio Diagnostics, Inc. 120
4.2.11 bioMérieux Vidas 121
4.2.12 Eisai Picolumi 121
4.2.13 Tosoh Medics, Inc. 121
4.3 New Technologies for Cancer Diagnostics 122
4.3.1 New and Improved Immunoassays 122
4.3.2 Immunohistochemical Tests 123
4.3.3 Molecular (DNA and Genomic) Diagnostic Assays 124
4.3.4 Genomics and Genetic Markers 125
4.3.5 Proteomics and New Protein Markers 126
4.3.5.1 Inside the ProteinChip System 126
4.3.5.2 Rapid Biological Assays on a Chip 126
4.3.5.3 Proteome Pattern Recognition 127
4.3.6 New Platform Technologies Including Flow Cytometry 127
4.3.7 Stem Cell Markers 130
4.3.8 Monoclonal Antibodies 130
4.3.9 Proteomics and Cancer Antibodies 134
4.3.10 Pharmacogenomics and Oncology Diagnostics 134
4.3.11 DNA Microarrays 137
4.3.12 In Vitro Diagnostic Multivariate Index Assays (IVDMIA) 139
4.3.13 Prostate PX Score 139
4.3.14 Prostate-63 139
4.3.15 Future Directions 139
4.4 Clinical Methods for Diagnosis of Cancer 140
4.4.1 Screening 140
4.4.2 Sigmoidoscopy 142
4.4.3 Imaging 142
4.4.4 Theranostics 144
5. Implications of Molecular Biology for New Diagnostic Cancer Tests 145
6. Companies Entering the Cancer Diagnostics Market with Novel Technology Platforms 146
6.1 Abbott Diagnostics 146
6.2 Affymetrix, Inc. 147
6.3 Agendia BV 148
6.4 Agensys, Inc. 148
6.5 Ambrilla Biopharma, Inc. 149
6.6 AMDL, Inc. 149
6.7 Asuragen, Inc. 151
6.8 Aureon Biosciences Corporation 151
6.9 Bard Diagnostics, Inc. 151
6.10 Bayer Diagnostics 152
6.11 Beckman Coulter, Inc. 152
6.12 Biocode S.A. 154
6.13 BioCurex 154
6.14 Biomedical Diagnostics 154
6.15 Biomerica 155
6.16 bioMérieux 155
6.17 Biomira 155
6.18 BioModa, Inc. 156
6.19 Bruker Daltonics 156
6.20 Byk Gulden 156
6.21 Cepheid 156
6.22 Clarient, Inc. 157
6.23 CytoCore (Formerly known as Molecular Diagnostics, Inc.) 159
6.24 Correlogic Systems, Inc. 159
6.25 Cytogen Corporation 159
6.26 diaDexus, LLC 162
6.27 DiagnoCure, Inc. 163
6.28 Diagnostic Products Corporation 164
6.29 Diagnostic Systems Laboratories, Inc. 164
6.30 DRG International, Inc. 164
6.31 Eisai Co., Ltd. 165
6.32 Enigma Diagnostics Ltd. 166
6.33 Epigenomics 166
6.34 Exact Sciences Corporation 166
6.35 Exagen Diagnostics, Inc. 167
6.37 Gene Logic, Inc. 167
6.38 Gen-Probe, Inc. 168
6.39 Genomic Health 168
6.40 Geron Corporation 169
6.42 Immunicon Corporation 170
6.43 Immunomedics, Inc. 174
6.44 Incyte Pharmaceuticals, Inc. 175
6.45 Ipsogen 175
6.46 LabCorp 175
6.47 Matritech 176
6.48 Mitsubishi Kagaku Medical 180
6.49 Molecular Devices (Formerly known as Arcturus Bioscience, Inc.) 180
6.50 Myriad Genetics, Inc. 180
6.51 Poniard Corporation 185
6.52 Nexell Therapeutics, Inc. 186
6.53 Northwest Biotherapeutics, Inc. 186
6.54 Nuvelo, Inc. 187
6.55 Panacea Pharmaceuticals, Inc. 187
6.56 Oncotech, Inc. 188
6.57 Polymedco, Inc. 189
6.58 Princeton BioMeditech Corporation 189
6.59 Qiagen 191
6.60 Sanko Junyaku Co., Ltd. 192
6.61 Tosoh Medics, Inc. 192
6.62 TriPath Imaging, Inc. 192
6.63 UroCor, Inc. 194
6.64 Ventana Medical Systems, Inc. 198
6.65 Veridex 199
6.66 Vermillion, Inc. (Formerly known as Ciphergen) 199
6.67 Worldwide Medical Corporation 200
6.68 Xenomics, Inc. 200
7. Business Trends in the Industry 201
7.1 Industry Consolidation 201
7.2 Breadth of Product Offering and Pricing 201
7.3 Government Regulation of Medical Devices 202
7.4 Strategic Business and Marketing Considerations 203
7.5 Commercial Opportunities in Cancer Markers 204
7.6 Moderators of Growth 205
7.7 Biotechnology Industry Trends 205
7.8 Pharmaceutical Industry Trends 206
7.9 Acquisition, License Agreement, Partnerships 208
7.10 Legal Developments 210
7.11 Sales and Marketing Strategies for Tumor Marker Tests 211
7.11.1 North American Market 212
7.11.2 International Markets 213
7.11.2.1 Europe 213
7.11.2.2 Central and South America 214
7.11.2.3 Asia/Pacific 214
8. Tumor Marker Testing: Important Issues 215
8.1 Trends in Patient Care and Reimbursement 215
8.2 Trends in Reimbursement Practice 216
8.3 Clinical Laboratory Improvement Act (CLIA) 218
8.4 Unmet Needs in Tumor Markers 219
9. Important New Technology Areas 220
9.1 Proteins 220
9.2 DNA Sequencing 221
9.3 The Human Genome Project (HGP) 222
9.4 Liquid Phase Chromatography 223
9.5 Polymerase Chain Reaction (PCR) 223
9.6 Capillary Electrophoresis 224
9.7 Proteomics 225
9.8 Use of Mass Spectroscopy in Sequencing 226
9.9 High-Throughput Organic Synthesis 230
10. New Cancer Markers in Basic Research 232
10.1 Genetics of Cancer 232
10.2 Telomerase 235
10.3 Stomach Cancer 237
10.4 Head and Neck Cancer 238
10.5 Breast Cancer 239
10.6 Prostate Cancer: p27 (Kip1) A New Molecular Marker for Prostate Cancer 240
10.7 PSMA 241
10.8 Cervical Cancer: NMPI79 242
10.9 Pancreatic Cancer: Peritoneal Cytology 242
10.10 Colorectal Cancer: CEA Doubling Time 242
10.11 Uterine and Kidney Cancer: MN/CA9 242
10.12 MMSC1 Scaffold Gene 242
10.13 p16 Tumor Suppressor Gene 243
10.14 MTS2 and p19 Cell Cycle Genes 243
10.15 Complement Factor H Related Proteins 243
10.16 MUC 2, 3, 4 243
10.17 Cytokeratins 244
10.18 Colon Cancer: Serum VEGF 244
10.19 Ras Oncogenes 244
10.20 Lung Cancer: Ribonucleoprotein A2/B1 245
10.21 BCLA-4 Matrix Protein 245
10.22 RAK Antigens 245
10.23 Serum Urokinase Receptors 245
10.24 Chips 246
10.25 Survivin 246
10.26 Human Endometrial Specific Steroid Binding Factor (hESF1) 24 |
|
|
|
Published By : TriMark Publications |
|
|
Category
Related Report:
Automotive,
Automobile,
Aerospace & Aviation,
Banking,
Consumer Goods,
Construction,
Chemicals,
Defense,
Diabetes,
Disease,
Drinks,
Energy,
Electronics,
Financial
,
Food & Drinks,
Glass,
Healthcare,
Insurance,
Information technology,
Investment,
Industrial Gases,
Industry Profile,
Medical,
Media,
Marketing,
Miscellaneous,
Metals & Mining,
Nuclear Energy,
Oil & Gas,
Power,
Real Estate,
Software,
Solar,
Transportation
|
|
|
|
